4.7 Article

Nuclear translocation of urokinase-type plasminogen activator

Journal

BLOOD
Volume 112, Issue 1, Pages 100-110

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2007-07-104455

Keywords

-

Categories

Funding

  1. FIC NIH HHS [5-R03-TW01468-03, R03 TW001468] Funding Source: Medline
  2. NCI NIH HHS [CA83121, R01 CA083121] Funding Source: Medline
  3. NEI NIH HHS [R01 EY015625, R01 EY015625-05] Funding Source: Medline
  4. NHLBI NIH HHS [HL076406, HL076206, R01 HL076206, P01 HL076406, R21 HL081864, 1 R21 HL82864-01] Funding Source: Medline

Ask authors/readers for more resources

Urokinase-type plasminogen activator (uPA) participates in diverse (patho)physiological processes through intracellular signaling events that affect cell adhesion, migration, and proliferation, although the mechanisms by which these occur are only partially understood. Here we report that upon cell binding and internalization, single-chain uPA (scuPA) translocates to the nucleus within minutes. Nuclear translocation does not involve proteolytic activation or degradation of scuPA. Neither the urokinase receptor (uPAR) nor the low-density lipoprotein-related receptor (LRP) is required for nuclear targeting. Rather, translocation involves the binding of scuPA to the nucleocytoplasmic shuttle protein nucleolin through a region containing the kringle domain. RNA interference and mutational analysis demonstrate that nucleolin is required for the nuclear transport of scuPA. Furthermore, nucleolin is required for the induction smooth muscle alpha-actin (alpha-SMA) by scuPA. These data reveal a novel pathway by which uPA is rapidly translocated to the nucleus where it might participate in regulating gene expression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available